GlassScriptPhysician profile
Samar M Charabaty
NPI 1467603365
$8,968.67
in general payments reported to CMS, 2019-2025
27 companies · $1,391 in 2025
The $1,391 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,134 · 2020: $701 · 2021: $1,144 · 2022: $1,429 · 2023: $1,400 · 2024: $1,771 · 2025: $1,391.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,434 · Education: $127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,433.98 |
| Education | $127.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,312.83 | 2019-2025 | Enbrel, Tavneos, Otezla |
| Abbvie INC. | $2,298.08 | 2019-2025 | Rinvoq, Humira, Skyrizi |
| Ucb, INC. | $743.99 | 2019-2025 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $705.15 | 2019-2025 | Tremfya |
| Glaxosmithkline, LLC. | $594.21 | 2019-2025 | Benlysta |
| Novartis Pharmaceuticals Corporation | $587.92 | 2019-2025 | |
| Pfizer INC. | $501.70 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $213.27 | 2021-2025 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $189.36 | 2020-2025 | Orencia |
| Mallinckrodt Hospital Products INC. | $134.13 | 2020-2024 | Acthar |
| Radius Health, INC. | $97.20 | 2021-2024 | Tymlos |
| Actelion Pharmaceuticals US, INC. | $88.48 | 2019-2023 | Opsumit |
| Aurinia Pharma U.S., INC. | $76.89 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $75.87 | 2019 | |
| Genentech USA, INC. | $45.85 | 2019-2024 | Actemra |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $45.79 | 2024 | Idacio, Tyenne |
| Alexion Pharmaceuticals, INC. | $38.94 | 2024 | Strensiq |
| Lilly USA, LLC | $34.24 | 2024-2025 | Taltz, Omvoh |
| Genzyme Corporation | $34.00 | 2020 | |
| Hospira, INC. | $29.64 | 2022-2024 | |
| Organon LLC | $25.19 | 2025 | Renflexis |
| Ani Pharmaceuticals, INC. | $22.23 | 2025 | Purified Cortrophin Gel |
| Sandoz INC. | $20.67 | 2025 | Jubbonti |
| Kiniksa Pharmaceuticals International, Plc | $20.03 | 2024 | Arcalyst |
| Merck Sharp & Dohme LLC | $15.72 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.46 | 2020 | |
| Fidia Pharma USA INC. | $5.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samar Charabaty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.